Biomarkers /
CREB3L2
Overview
cAMP responsive element binding protein 3-like 2 (CREB3L2) is a gene that encodes a protein that functions as a transcriptional activator. Fusions, rearrangements, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
CREB3L2 is altered in 0.13% of all cancers with low grade fibromyxoid sarcoma, breast invasive ductal carcinoma, lung adenocarcinoma, glioblastoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in CREB3L2 are CREB3L2-FUS Fusion (0.01%), CREB3L2-EWSR1 Fusion (0.01%), CREB3L2 P444L (0.28%), CREB3L2 T100S (5.88%), and CREB3L2-PPARG Fusion (0.02%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.